SecBot SecBot
8-K ·Filed Apr 13, 2026

PHGE

BiomX Inc.
BULLISH
Impact 7/10
Horizonweeks Processed7mo ago SEC0001213900-26-042811
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ▲ Bullish

Monitor shareholder approval process and Israel Innovation Authority regulatory clearance. The integration of DFSL's technology with BiomX's existing Zorronet platform could create synergies in AI-enabled security systems, but execution risk remains.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.63
T+0 close · Apr 13, 2026 · via day close
Latest settled
−89.51%
T+60 · $0.2758
Vs SPY
−98.44%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 13 $2.63entry
  2. T+1 · 7mo ago −15.97%α −17.18% · $2.21
  3. T+5 · 7mo ago −44.49%α −47.78% · $1.46
  4. T+20 · 6mo ago −74.30%α −82.02% · $0.6760
  5. T+60 · 4mo ago −89.51%α −98.44% · $0.2758
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BiomX Inc. completed the acquisition of DFSL, a defense technology company, using a combination of cash, a convertible note, stock, and warrants. The deal expands BiomX's presence in the defense and security sector with AI-powered detection systems. The transaction is subject to shareholder and regulatory approval.

Key Financial Metrics

Deal Value
$3.8M
Deal Type
acquisition

Key Facts

  • BiomX acquired 60% of DFSL for $750,000 in cash, a $3 million convertible note, 923,000 shares of stock, pre-funded warrants for 923,000 shares, and a five-year warrant for 3,692,000 shares
  • The acquisition strengthens BiomX's position in AI-enabled security systems with DFSL's LADAR-based detection technology
  • The transaction is subject to shareholder approval for issuances exceeding 19.99% of outstanding shares and regulatory approval from the Israel Innovation Authority
  • Mandragola will provide a credit line to support DFSL's development and debt payment
  • A revenue bonus of 5% of annual revenues above $25 million is tied to future performance

Financial Impact

Total deal value of $3.75 million in cash and securities, with potential additional payments based on revenue performance

debtdilutionrevenuestrategic positioning

Risk Factors

  • Failure to obtain shareholder approval for the stock issuances
  • Regulatory delays from the Israel Innovation Authority
  • Integration challenges between DFSL's technology and BiomX's existing platforms

Market Snapshot

Exchange
NYSE
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 9 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-042811
Document: ea028529301ex10-1.htm0001213900-26-042811
Document: ea028529301ex4-2.htm0001213900-26-042811
Document: ea0285293-8k_biomx.htm0001213900-26-042811
Document: ea028529301ex4-1.htm0001213900-26-042811
Document: ea028529301ex99-1.htm0001213900-26-042811
Document: 0001213900-26-042811-index-headers.html0001213900-26-042811
Document: 0001213900-26-042811-index.html0001213900-26-042811
Document: 0001213900-26-042811.txt0001213900-26-042811

US Market Status

Market Closed · Opens in 4h 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 13, 2026